Zydus Cadila receives tentative USFDA approval for deferasirox tablets

The company has been granted the tentative approval from the USFDA to market deferasirox tablets in 90 mg, 180 mg, and 360 mg. The medication will be manufactured at the group’s facility in SEZ, Ahmedabad.

Deferasirox is the registered listed drug in the US market, and sold by Swiss drug major Novartis as Exjade Tablets. Deferasirox is an iron chelator prescribed for the treatment of chronic iron overload, which is mostly caused by multiple blood transfusions. The drug is also used to treat ongoing high levels of iron in the body for people blood disorder like non-transfusion dependent thalassemia (NTDT) syndromes.

Last week, Zydus receives final USFDA approval for antiretroviral drugs Abacavir & Lamivudine Tablets. It also received approval for Fondaparinux Injection. Zydus Cadila group now has 231 approvals and has filed over 340 ANDAs as of date, since FY2003-04.

Despite this development, at 12:35 hours, the stock of Zydus Cadila, which is listed as Cadila Healthcare on the Indian exchanges was trading at Rs. 358.10 per share, down by 1.80 per cent on Tuesday. The stock opened at Rs. 363.90 per share.